trending Market Intelligence /marketintelligence/en/news-insights/trending/_aq-_-ky3chnbfgima6ocg2 content esgSubNav
In This List

Biogen, AbbVie withdraw MS drug after encephalitis reports

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Biogen, AbbVie withdraw MS drug after encephalitis reports

AbbVie Inc. and Biogen Inc. are withdrawing marketing authorizations worldwide for multiple sclerosis treatment Zinbryta due to safety issues.

The withdrawal comes after reports of encephalitis, a swelling of the brain, and meningoencephalitis, an inflammation of brain tissue and the spinal cord, were associated with the drug.

The European Medicines Agency previously recommended that use of the drug be restricted to patients that had an inadequate response to two other multiple sclerosis treatments after the death of a patient and four cases of serious liver injury.